Plexxikon is an American drug discovery company based in South San Francisco, California. It was co-founded in 2001 by Joseph Schlessinger of Yale University, and Sung-Hou Kim of the University of California, Berkeley.
| Company type | Subsidiary |
|---|---|
| Industry | Biotechnology |
| Founded | 2001 |
| Founder | Joseph Schlessinger |
| Defunct | 2011 |
| Fate | Acquired by the Daiichi Sankyo |
| Headquarters | South San Francisco, California, United States. |
| Website | www |
It uses a proprietary structural biology-based platform called Scaffold-Based Drug Discovery to build a pipeline of products in multiple therapeutic areas. This discovery process integrates multiple technologies, including structural screening as one key component, that it hopes will give a significant competitive advantage over other approaches.[citation needed][1]
In April 2011, Plexxikon was acquired by the Japanese pharmaceutical company Daiichi Sankyo for $805 million and an additional $130 million in potential milestone payments.[2][3][4]
Daiichi Sankyo announced the shutdown of Plexxikon in 2022.[5]
Drug pipeline
edit- Vemurafenib (Zelboraf) and pexidartinib (Turalio) are two FDA approved drugs developed by Plexxikon
- Plexxikon is collaborating with Wyeth Pharmaceuticals on several products for use in type II diabetes and other metabolic disorders.[6] The most advanced of these agents is indeglitazar (PLX204), which is currently in Phase II clinical trials for type 2 diabetes.[7]
See also
editReferences
edit- ^ "AI Drug Discovery: Key Trends and Developments in Pharmaceutical Industry". www.biopharmatrend.com. Retrieved 2023-09-11.
- ^ "Daiichi Sankyo to Acquire Plexxikon". Plexxikon. 2011-02-28. Archived from the original on 2011-03-06.
- ^ "Plexxikon acquired by Daiichi Sankyo". Haberman Associates. 2011-03-03. Retrieved 2020-08-06.
- ^ "Daiichi Sankyo, Inc. Completes Plexxikon Inc. Acquisition". BioSpace. Retrieved 2020-08-06.
- ^ Wells, Madeline (2022-01-12). "South SF company bought for $800 million is being shut down". SFGATE. Archived from the original on 2022-01-12.
- ^ "Wyeth, Plexxikon tie up to develop novel diabetes & metabolic disorders treatment". 28 October 2004. Archived from the original on 24 October 2007.
- ^ "Study Evaluating PPM-204 In Subjects With Type 2 Diabetes - Full Text View - ClinicalTrials.gov". Clinical Trials. 18 December 2007. Retrieved 2020-10-09.
- ^ "Fms/Trk tyrosine kinase inhibitor PLX7486". NCI Drug Dictionary. National Cancer Institute.
- ^ "Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors". ClinicalTrials.gov. 2018-08-02. Archived from the original on 2021-11-17.